The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras through iRGD Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer
Abstract
Proteolysis-targeting chimeras (PROTACs) have recently emerged as a promising technology for drug development. However, poor water solubility, limited tissue selectivity, and inadequate tumor penetration pose significant challenges for PROTAC-based therapies in cancer treatment. Herein, we developed an iRGD-PROTAC conjugation strategy utilizing tumor-penetrating cyclic peptide iRGD (CRGDK/RGPD/EC) to deliver PROTACs deep into breast cancer tissues. As a conceptual validation study, iRGD peptides were conjugated with a bromodomain-containing protein 4 (BRD4) PROTAC through a GSH-responsive linker. The resulting iRGD-PROTAC conjugate iPR showed enhanced water solubility, tumor-targeting capability, and penetration within tumor tissues, resulting in increased antibreast cancer efficacy in animal models and patient-derived organoids. This study demonstrates the advantages of combining iRGD and PROTACs in improving drug delivery and highlights the importance of tissue selectivity and penetration ability in PROTAC-based therapeutics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In an MDA-MB-231 xenograft model, PRO achieved a TGI of 36.3% (vs PBS), whereas iPR reached 62.3% (5 μM) and 81.5% (8 μM) after 21 days (vs PBS), supporting a quantitatively stronger in vivo benefit than the parent PROTAC at matched/near-matched dosing.”
From Overcoming tumor microenvironment barriers: transformable and bioinspired nanomedicine strategies for deep tumor penetration (2026) · cites this paper as [81]
In the citing paper
“iRGD conjugation to a BRD4 PROTAC via a GSH-responsive disulfide carbonate linker (iPR) improves solubility, enables αvβ3/NRP1-dependent uptake and CendR permeation, and strengthens BRD4 degradation and antitumor effects versus the parent small molecule [81].”
From Overcoming tumor microenvironment barriers: transformable and bioinspired nanomedicine strategies for deep tumor penetration (2026) · cites this paper as [81]
Citations
Cites
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096
Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity
Cantuti-Castelvetri, L., Ojha, R., Pedro, L. D., Djannatian, M., Franz, J., Kuivanen, S., van der Meer, F., Kallio, K., Kaya, T., Anastasina, M., et al. (2020) · Science · doi:10.1126/science.abd2985 · Cited by 1,925
PROTACs: past, present and future
Li, K., & Crews, C. M. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00193d · Cited by 869
Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity
Overacre-Delgoffe, A. E., Chikina, M., Dadey, R. E., Yano, H., Brunazzi, E. A., Shayan, G., Horne, W., Moskovitz, J. M., Kolls, J. K., Sander, C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.005 · Cited by 627
Cotton, A. D., Nguyen, D. P., Gramespacher, J. A., Seiple, I. B., & Wells, J. A. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c10008 · Cited by 551
Discovery of a Covalent FEM1B Recruiter for Targeted Protein Degradation Applications
Henning, N. J., Manford, A. G., Spradlin, J. N., Brittain, S. M., Zhang, E., McKenna, J. M., Tallarico, J. A., Schirle, M., Rape, M., & Nomura, D. K. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c03980 · Cited by 221
Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity
Pillow, T. H., Adhikari, P., Blake, R. A., Chen, J., Del Rosario, G., Deshmukh, G., Figueroa, I., Gascoigne, K. E., Kamath, A. V., Kaufman, S., et al. (2020) · ChemMedChem · doi:10.1002/cmdc.201900497 · Cited by 216
Amide-to-Ester Substitution as a Strategy for Optimizing PROTAC Permeability and Cellular Activity
Klein, V. G., Bond, A. G., Craigon, C., Lokey, R. S., & Ciulli, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01496 · Cited by 152
Research works printed but not linked: 30
- 10.1038/s41573-021-00371-6 · DOI · Paper page
- 10.1038/s41568-021-00365-x · DOI
- 10.1038/s41589-019-0362-y · DOI · Paper page
- 10.1002/med.21877 · DOI
- 10.1016/j.cell.2019.11.031 · DOI · Paper page
- 10.1016/j.cej.2023.143883 · DOI
- 10.1002/anie.202107347 · DOI
- 10.1021/jacs.1c00451 · DOI
- 10.1038/s41467-021-23194-w · DOI
- 10.1021/acschembio.0c00285 · DOI · Paper page
- 10.1038/nm720 · DOI
- 10.1016/j.addr.2016.03.008 · DOI
- 10.1038/nrc3627 · DOI
- 10.1016/S0092-8674(00)81402-6 · DOI
- 10.1073/pnas.2112457118 · DOI
- 10.1073/pnas.0908201106 · DOI · Paper page
- 10.1182/blood-2008-04-150342 · DOI
- 10.1016/j.addr.2015.12.001 · DOI
- 10.1016/j.ccr.2009.10.013 · DOI
- 10.1016/j.jconrel.2016.06.032 · DOI
- 10.1186/s13045-020-00885-3 · DOI
- 10.1016/j.chembiol.2015.05.009 · DOI · Paper page
- 10.1073/pnas.1521738113 · DOI · Paper page
- 10.1021/acs.jmedchem.8b01196 · DOI
- 10.1016/j.biomaterials.2014.06.042 · DOI
- 10.1016/j.drudis.2022.103387 · DOI
- Gasparini G., 1998, Clin. Cancer Res., 4, 2625
- 10.1016/j.semcancer.2019.08.012 · DOI
- 10.1172/JCI92284 · DOI
- 10.1038/s41467-017-01565-6 · DOI
Cited by
Sorted by citations
Sheng, J., Yuan, W., Zhang, M., Chen, Z., Qi, Y., Zhao, Y., & Zhang, S. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04028-7 · Cited by 35
Metadata
- Authors
- He, S., Fang, Y., Wu, M., Zhang, P., Gao, F., Hu, H., Sheng, C., & Dong, G.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2023-12-06
- Volume
- 66
- Issue
- 24
- Pages
- 16828-16842
- ISSN
- 0022-2623
- 1520-4804
- Cited by
- 42
- References
- 8
- Language
- en
- Licence
- Funders
- National Key Research and Development Program of China (2022YFC3401500)
- National Natural Science Foundation of China (82030105, 82273779, 82003567)
- Shanghai Rising-Star Program (23QA1403500)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras through iRGD Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer. https://app.cochat.ai/papers/10.1021/acs.jmedchem.3c01539
- The paper
- He, S., Fang, Y., Wu, M., Zhang, P., Gao, F., Hu, H., Sheng, C., & Dong, G. (2023). Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras through iRGD Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01539